Naloxegol

BreastfeedingPediatric
  • TRADE NAME: Movantik (AstraZeneca)
  • INDICATIONS: Opioid-induced constipation
  • CLASS: Opioid receptor antagonist
  • HALF-LIFE: 6–11 hours

FDA APPROVAL DATE: 09/16/2014

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Diltiazem, Erythromycin, Grapefruit Juice, Verapamil

PREGNANCY CATEGORY: C

Contra-indicated in patients with known or suspected gastrointestinal obstruction, patients at increased risk of recurrent gastrointestinal obstruction, and patients concomitantly using strong CYP3A4 inhibitors.

Our database has 13 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
NEUROMUSCULAR/SKELETAL.
OTHER.


Page last updated 05/08/2020

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top